Levodopa prolongs life expectancy and is non-toxic to substantia nigra
Section snippets
Introduction and background
Parkinson's disease (PD) is characterized by marked loss of substantia nigra (SN) pigmented neurons. Whether it is single event or a prolonged process which produces the pathological changes is unknown [1]. It is a progressive disease but the rate of decline varies among patients. The rate of worsening after Stage 2 Hoehn & Yahr [2] however is distinctive for each patient [3]. Although PD is concentrated in older age the aging process does not produce subregional SN neuronal loss characteristic
Material and patients
All patients included in this study were seen by the author personally.
We studied life expectancy in 934 consecutive PS patients assessed at the Movement Disorder Clinic Saskatoon (MDCS) over a 22 year period (1968–1990) [20]. The survival was measured from the date of first MDCS visit. Patients were then divided into those who had onset and MDCS visit before 1st January 1974—highly restricted access to LD and those who had an unrestricted LD access. Survival in each group was compared with sex
Results
Fig. 1 shows that life expectancy in the entire group of 934 PS patients compared to that expected in the matched general population was significantly shorter (P<0.0001). Prior to 1st January 1974, 215 of these patients were assessed at MDCS (had onset). The access to LD in this subgroup was extremely restricted as the patients often needed to attend MDCS to obtain LD prescription. Survival in these 215 patients compared with that expected is seen in Fig. 2. There was markedly reduced life
Discussion
The impact of LD on life expectancy has been a topic of many studies [26]. Our 22 year study of 934 patients is, to my knowledge, the largest such report, and the only report from one centre which assessed survival in patients prior to and subsequent to the widespread use of LD. As expected, the survival in this chronic illness is compromised and even today, remains significantly shorter than expected (Fig. 3). The benefit of LD to survival is evident when the shortened life expectancy in those
References (30)
- et al.
Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice
Brain Res
(1996) - et al.
Timely levodopa (LD) administration prolongs survival in Parkinson's disease
Parkinsonism & Related Disorders
(1997) Is idiopathic parkinsonism the consequence of an event or a process
Neurology
(1994)- et al.
Parkinsonism: onset, progression, and mortality
Neurology
(1967) - et al.
Disability and progression of Parkinson's disease
Acta Neurol Scand
(1977) - et al.
Ageing and Parkinson's disease: Substantia nigra regional selectivity
Brain
(1991) - et al.
Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain: their behaviour in extrapyramidal system diseases
Klin Wochenschr
(1960) - et al.
The effect of L-3,4-dihydroxyphenylalanine (=L-DOPA) on akinesia in Parkinsonism
Wiener Klinische Wochenschrift
(1961) - et al.
Aromatic amino acids and modification of parkinsonism
N Engl J Med
(1967) - et al.
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases
Arch Neurol
(1982)
Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease
J Neurochem
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
N Engl J Med
The pathology of parkinsonism: a comparison of degenerations in cerebral cortex and brainstem
The oxidant stress hypothesis in Parkinson's disease: evidence supporting it
Ann Neurol
L-DOPA cytotoxicity to PC12 cells in culture is via its autoxidation
J Neurochem
Cited by (68)
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats
2018, Biomedicine and PharmacotherapyCitation Excerpt :Until now, there is no disease-modifying therapy that has been testified to be effective to prevent its progression. Treatment of PD is still based on the use of L-3,4-dihydroxyphenylalanine (L-dopa), which has been regarded as the gold-standard treatment for over many years [3]. Compared with other available dopaminergic treatments, L-dopa therapy is featured with the greatest improvement in motor function [4].
Metabotropic glutamate receptors and neurodegenerative diseases
2017, Pharmacological ResearchSystematic review on factors associated with medication non-adherence in Parkinson's disease
2012, Parkinsonism and Related DisordersCitation Excerpt :Parkinson's disease (PD) is a disabling condition which substantially reduces quality of life (QoL) [1]. Levodopa remains the most efficacious treatment by replenishing dopaminergic tone in the nigrostriatal pathway; the use of which is associated with increased QoL and life expectancy [2]. Although monotherapy represents usual early phase management, more than half of PD patients take two-to-four anti-parkinsonian medications three-to-four times daily [3].
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
2012, Neurobiology of DiseaseCitation Excerpt :The dose requirement to saturate l-DOPA in rats corresponds to the needs of an intermediate- or advanced disease PD patient, suggesting an insufficient uptake of l-DOPA to the brain, which might be an important limiting factor in peripheral l-DOPA therapy. In the early stages of the disease l-DOPA improves not only the activities of daily living and quality of life but also independence and employability (Rajput, 2001). Patients have a so-called ‘honeymoon’ period where they experience a continuous robust response to relatively low doses of l-DOPA (Olanow et al., 2009).
Animal models of the non-motor features of Parkinson's disease
2012, Neurobiology of DiseaseCitation Excerpt :Following the work of Carlsson et al. (1957), replacement of DA via administration of 3,4-Dihydroxyphenylalanine (L-DOPA) has remained the most common and effective treatment for patients (Vlaar et al., 2011). L-DOPA treatment usually improves motor functioning and is associated with a drop in mortality levels (Rajput, 2001), but side effects, primarily drug-induced dyskinesia, can severely reduce treatment benefits. The availability of direct DA agonists and modifiers of DA metabolism, as well as deep brain stimulation, have helped improve the symptomatic treatment of the cardinal motor symptoms of PD (Bronstein et al., 2011; Factor, 2008).